Hemorrhagic Stroke Market

Hemorrhagic Stroke Market by Treatment (Devices [Embolization Devices, Aneurysm Treatment Devices, Clot Retrieval Devices / Stent Retrievers, and Hemostatic Clips and Catheters] and Drugs [Antihypersensitives, Anti-Coagulants, Anti-Convulsants, and Others]), Diagnosis Type (Magnetic Resonance Imaging (MRI), Computed Tomography, Cerebral Angiography, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing incidence of hemorrhagic stroke, rising prevalence of risk factors such as hypertension, diabetes, and obesity, and growing adoption of minimally invasive procedures.

The hemorrhagic stroke market is estimated to grow at a CAGR of 5.13% during the forecast period from 2025 to 2032. The increasing incidence of hemorrhagic stroke, along with the rising prevalence of risk factors like hypertension, diabetes, and obesity, is significantly driving the market for hemorrhagic stroke devices. These chronic conditions elevate the risk of intracerebral bleeding, leading to a greater demand for effective treatment solutions. Additionally, the growing preference for minimally invasive procedures such as endovascular coiling and flow diversion reduces surgical risks, recovery time, and hospital stays, encouraging wider adoption. Simultaneously, companies are actively investing in product development to launch innovative neurovascular devices, such as next-generation stent retrievers and embolization systems, further propelling market growth. Together, these factors are expected to drive the growth of the hemorrhagic stroke market during the forecast period from 2025 to 2032.

Hemorrhagic Stroke Market Dynamics:

According to the World Stroke Organization (2022), over 3.4 million new cases of intracerebral hemorrhagic stroke occur globally each year, accounting for more than 28% of all stroke incidents. Additionally, approximately 1.2 million new subarachnoid hemorrhagic strokes are reported annually. Notably, over 23% of intracerebral hemorrhagic strokes and 28% of subarachnoid hemorrhagic strokes affect individuals aged 15–49.  

With the rising incidence of these life-threatening conditions, there is an increasing demand for advanced diagnostic tools such as CT scans, MRI, and cerebral angiography to enable rapid and accurate detection of brain hemorrhages. Similarly, the need for effective treatment solutions including endovascular coiling, aneurysm clipping, and flow-diverting stents has fueled the adoption of minimally invasive neurosurgical techniques, thereby driving market growth.  

Moreover, ongoing product development and clinical advancements are further propelling the hemorrhagic stroke market. For instance, in July 2022, Instylla Inc. announced positive preclinical results for its Embrace™ Hydrogel Embolic System in hemorrhage models, highlighting innovations in stroke management.  

Overall, these factors are expected to drive significant market growth from 2025 to 2032. However, challenges such as the risk of rebleeding due to poor risk factor management (e.g., hypertension) and an increasing number of product recalls may pose obstacles to market expansion.

Hemorrhagic Stroke Market Segment Analysis:

Hemorrhagic Stroke Market by Treatment (Devices [Embolization Devices, Aneurysm Treatment Devices, Clot Retrieval Devices / Stent Retrievers, and Hemostatic Clips and Catheters] and Drugs [Antihypersensitives, Anti-Coagulants, Anti-Convulsants, and Others]), Diagnosis Type (Magnetic Resonance Imaging (MRI), Computed Tomography Scanners, Cerebral Angiography, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment segment of the hemorrhagic stroke market, embolization devices are projected to capture a significant revenue share in 2024. These devices play a crucial role in advancing hemorrhagic stroke treatment by offering effective, minimally invasive solutions for managing conditions such as intracranial aneurysms and arteriovenous malformations (AVMs). Designed to occlude blood vessels at risk of rupture, embolization devices including coils, plugs, and liquid embolic agents help prevent further bleeding and significantly reduce the likelihood of recurrent hemorrhagic strokes.  

The growing incidence of hemorrhagic strokes, driven by rising risk factors such as hypertension and diabetes, has fueled the demand for advanced therapeutic options like embolization. Additionally, as global healthcare systems increasingly prioritize minimally invasive procedures to enhance patient outcomes and reduce recovery times, embolization devices provide a compelling alternative to traditional surgical approaches, which often involve higher risks and prolonged hospital stays.  

Technological advancements have further improved the efficacy and safety of these devices, contributing to better patient outcomes and greater adoption among healthcare professionals. For instance, in March 2024, CERENOVUS Inc., a key player in neurovascular care and part of Johnson & Johnson MedTech, launched the TRUFILL™ n-BCA Liquid Embolic System Procedural Set. This new addition to the CERENOVUS hemorrhagic stroke portfolio introduced a streamlined, sterilized set with two configurations and essential accessories for delivering the n-BCA Liquid Embolic System, simplifying procedural preparation and enhancing efficiency.  

Collectively, these factors are expected to drive significant growth in the hemorrhagic stroke treatment market worldwide.  

North America is expected to dominate the overall hemorrhagic stroke market:

North America is projected to hold the largest share of the hemorrhagic stroke market in 2024. Several key factors contribute to this dominance, including a high prevalence of risk factors such as hypertension, diabetes, and obesity, which significantly increase the incidence of hemorrhagic strokes. Additionally, growing awareness about stroke symptoms and the importance of timely medical intervention has led to higher treatment adoption rates, further driving market growth.  

The region is also at the forefront of research and development (R&D) in stroke management, with pharmaceutical and medical device companies investing heavily in innovative therapies and advanced treatment solutions. These efforts have led to groundbreaking developments in hemorrhagic stroke care, reinforcing North America's leadership in the market.  

Obesity is a major risk factor for hemorrhagic stroke, significantly influencing market expansion. According to the Centers for Disease Control and Prevention (CDC, 2024), 9.2% of U.S. adults had severe obesity, with over 100 million adults classified as obese and 22 million affected by severe obesity. Obesity exacerbates other stroke-related conditions, including hypertension, diabetes, and hyperlipidemia, all of which contribute to the rising incidence of hemorrhagic stroke. As obesity rates continue to rise globally, the demand for both preventive care and advanced stroke treatment solutions is expected to grow.  

Diabetes is another significant contributor to hemorrhagic stroke risk, as it is often accompanied by comorbidities such as hypertension and cardiovascular diseases, which weaken blood vessels and increase the likelihood of hemorrhagic events. The CDC (2021) estimated that 38.4 million people in the U.S. (11.6% of the total population) had diabetes, including 38.1 million adults (14.7% of U.S. adults aged 18 and older). As diabetes prevalence continues to climb, so does the incidence of hemorrhagic strokes, increasing the demand for effective treatment and management solutions. This growing burden on healthcare systems is driving innovation and investment in advanced medical devices and therapies aimed at diagnosing and treating hemorrhagic strokes.  

Ongoing strategic initiatives by key market players are further accelerating the growth of the hemorrhagic stroke market in North America. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Heuron ICH, an AI-enabled software designed to facilitate the timely detection and triage of intracranial hemorrhages. Such technological advancements improve diagnostic efficiency and patient outcomes, fueling market expansion.  

Collectively, these factors including the rising prevalence of obesity and diabetes, increasing demand for advanced treatment solutions, robust R&D investments, and technological innovations are expected to significantly drive the hemorrhagic stroke market in North America over the forecast period.  

Hemorrhagic Stroke Market Key Players:

Some of the key market players operating in the Hemorrhagic Stroke market include Medtronic PLC, MicroVention Inc., Stryker, Penumbra Inc., NICO Corporation, CERENOVUS Inc., Instylla Inc., Terumo Corporation, Phenox GmbH, Abbott, Siemens Healthineers, Bayer AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sanofi, AstraZeneca, Novo Nordisk, Siemens Healthineers, GE Healthcare, Rapid Medical, and others.

Recent Developmental Activities in the Hemorrhagic Stroke Market:

• In June 2024, Penumbra announced the CE Mark and European launch of BMX™81 and BMX™96. These devices are designed for neurovascular management of ischemic and hemorrhagic stroke and are Penumbra’s most advanced neuro access offerings.
• In October 2022, NICO Corporation announced the completion of enrollment for the ENRICH trial, which compared medical and economic outcomes of early surgical intervention for intracerebral hemorrhage (ICH) using minimally invasive parafascicular surgery (MIPS) versus standard medical management. It was the first ICH trial to use the brain’s natural folds (trans-sulcal) for access and adaptively enroll patients based on ICH location for optimal benefit.

Key Takeaways From the Hemorrhagic Stroke Market Report Study

• Market size analysis for current hemorrhagic stroke size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the hemorrhagic stroke market.
• Various opportunities available for the other competitors in the hemorrhagic stroke market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current hemorrhagic stroke market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hemorrhagic stroke market growth in the coming future?

Target Audience Who Can be Benefited From This Hemorrhagic Stroke Market Report Study

• Hemorrhagic stroke product providers
• Research organizations and consulting companies 
• Hemorrhagic stroke-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in hemorrhagic stroke 
• Various end-users who want to know more about the hemorrhagic stroke market and the latest technological developments in the hemorrhagic stroke market.  

Frequently Asked Questions for the Hemorrhagic Stroke Market:

1. What is hemorrhagic stroke?

• A hemorrhagic stroke occurs when a blood vessel in the brain bursts, leading to bleeding within or around the brain tissue. This disrupts normal blood flow, causing brain cells to be damaged or die due to pressure buildup and lack of oxygen. It can result from conditions like high blood pressure, trauma, aneurysms, or arteriovenous malformations (AVMs). 

2. What is the market for hemorrhagic stroke?

• The hemorrhagic stroke market is estimated to grow at a CAGR of 5.13% during the forecast period from 2025 to 2032. 

3. What are the drivers for the global hemorrhagic stroke market?

• The increasing incidence of hemorrhagic stroke, along with the rising prevalence of risk factors like hypertension, diabetes, and obesity, is significantly driving the market for hemorrhagic stroke devices. These chronic conditions elevate the risk of intracerebral bleeding, leading to a greater demand for effective treatment solutions. Additionally, the growing preference for minimally invasive procedures such as endovascular coiling and flow diversion reduces surgical risks, recovery time, and hospital stays, encouraging wider adoption. Simultaneously, companies are actively investing in product development to launch innovative neurovascular devices, such as next-generation stent retrievers and embolization systems, further propelling market growth. Together, these factors are expected to boost consumer engagement and drive the growth of the hemorrhagic stroke market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global hemorrhagic stroke market?

• Some of the key market players operating in the hemorrhagic stroke are Medtronic PLC, MicroVention Inc., Stryker, Penumbra Inc., NICO Corporation, CERENOVUS Inc., Instylla Inc., Terumo Corporation, Phenox GmbH, Abbott, Siemens Healthineers, Bayer AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sanofi, AstraZeneca, Novo Nordisk, Siemens Healthineers, GE Healthcare, Rapid Medical, and others.

5. Which region has the highest share in the global hemorrhagic stroke market?

• North America is expected to account for the highest proportion of the hemorrhagic stroke market in 2024, out of all regions. Firstly, the region has a high prevalence of risk factors such as hypertension, diabetes, and obesity, which contribute to the rising incidence of hemorrhagic strokes. Furthermore, increased awareness about stroke symptoms and the importance of timely intervention has led to more individuals seeking medical care, thus driving demand for effective treatment options. Collectively, these factors position North America as a leader in the hemorrhagic stroke market, facilitating improved patient outcomes and growth in this healthcare segment.